Clinical Trial: Riptylimab for the Treatment of Optic Neuritis and Myelitis Spectrum Diseases

U.S., July 7 -- ClinicalTrials.gov registry received information related to the study (NCT07685678) titled 'Riptylimab for the Treatment of Optic Neuritis and Myelitis Spectrum Diseases' on June 29.

Brief Summary: This clinical trial aims to evaluate the safety and efficacy of ripertamab in patients with neuromyelitis optica spectrum disorders (NMOSD). The key research objectives are as follows:

1. To assess the efficacy of ripertamab for the treatment of neuromyelitis optica spectrum disorders.

2. To assess the safety of ripertamab for the treatment of neuromyelitis optica spectrum disorders.

Study participants are required to:

Receive a single intravenous infusion of ripertamab. Attend follow-up examinations and laboratory tests at t...